Citadel Advisors
KYTH

Citadel Advisors’s KYTHERA BIOPHARMACEUTICALS, INC COM KYTH Stock Holding History

Citadel Advisors’s Portfolio KYTH Stock Details KYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-3,300
Closed -$247K – 9747
2015
Q3 		$247K Sell
3,300
-6,600
-67% -$493K ﹤0.01% 5847
2015
Q2 		$746K Sell
9,900
-6,900
-41% -$370K ﹤0.01% 4378
2015
Q1 		$843K Buy
16,800
+14,100
+522% +$592K ﹤0.01% 4159
2014
Q4 		$94K Buy
2,700
+100
+4% +$3.49K ﹤0.01% 6696
2014
Q3 		$85K Buy
+2,600
New +$91.6K ﹤0.01% 6553
2014
Q2 		– Sell
-4,700
Closed -$187K – 8646
2014
Q1 		$187K Sell
4,700
-600
-11% -$26.8K ﹤0.01% 5584
2013
Q4 		$197K Buy
+5,300
New +$220K ﹤0.01% 5044

Citadel Advisors's KYTH Position: Q4 2015 in Review

Citadel Advisors sold out of KYTHERA BIOPHARMACEUTICALS, INC COM (KYTH) in Q4 2015, closing a stake of 45,657 shares — an estimated $3.42M sold.

Citadel Advisors first reported a position in KYTH in Q3 2013 and held it in 7 quarters. The position peaked at $45.6M in Q2 2015. 0 funds tracked by Wall St. Rank hold KYTH as of Q4 2015.

  • Citadel Advisors reported no remaining KYTHERA BIOPHARMACEUTICALS, INC COM position as of Q4 2015 after selling out during the quarter.
  • Citadel Advisors sold 45,657 KYTHERA BIOPHARMACEUTICALS, INC COM shares in Q4 2015, an estimated $3.42M.
  • Citadel Advisors first reported a position in KYTHERA BIOPHARMACEUTICALS, INC COM in Q3 2013 and held it in 7 quarters.
  • Citadel Advisors's KYTHERA BIOPHARMACEUTICALS, INC COM position peaked at $45.6M in Q2 2015.
  • 0 funds tracked by Wall St. Rank held KYTHERA BIOPHARMACEUTICALS, INC COM as of Q4 2015.

Based on Citadel Advisors's 13F filing for Q4 2015, filed 12 Feb 2016.